StockData

NewAmsterdam Pharma vs Stoke Therapeutics

NAMS and STOK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NAMS and STOK compare

Stoke Therapeutics grew revenue faster over the last twelve months (−86.2% versus −88.9% for NewAmsterdam Pharma).

Stoke Therapeutics keeps more of each dollar of sales as profit, with a net margin of −754% compared with −3644% at NewAmsterdam Pharma.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNAMSSTOK
Size and price
Market cap–$1.7B
Share price$19.39$26.41
Change, 1 year−49.4%−0.38%
Change, 5 years98.1%5.2%
Beta (5Y)1.570.98
Employees100170
StockData Score
Total score66
Valuation score00
Growth score01 (better)
Performance score1 (better)0
Health score55
Dividend score00
Valuation
P/S–61.8×
P/B–4.9×
FCF yield–−10.6%
Fair value–$9.66
Margin of safety–−173%
Growth
Revenue growth (TTM)−88.9%−86.2% (better)
Net income growth (TTM)–−496%
EPS growth (TTM)–−501%
Profitability
Operating margin−3432%−810% (better)
Net margin−3644%−754% (better)
FCF margin−2018%−655% (better)
Return on equity−36.8% (better)−61.1%
Return on invested capital−1046%−252% (better)
Financial health
Debt / equity0.000.00
Interest coverage–−4856.0×
Current ratio9.03 (better)7.69
Altman Z-score–18.01
Piotroski F-score35 (better)
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions–120%
Held by insiders22.0%41.6%
Insider net buying, 12 months−$63.0M−$6.7M (better)
Short interest, % of float–28.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.